Swiss Series A company supplying cell-free synthetic DNA constructs and the Hybridosome™ nanoparticle delivery technology for non-viral gene therapy applications.
Anjarium Biosciences is a cell and gene therapy tools and technology company headquartered in Switzerland. It supplies researchers and manufacturers with DNA constructs and related tools intended to shorten the discovery and delivery cycle of genetic medicines. The company describes its position as the interface of genetic medicine, synthetic biology and nanoparticle engineering.
Its technology base rests on three elements. An enzymatic, cell-free platform produces pure, stable and customizable synthetic DNA constructs at scale, without the constraints of cell-based synthesis. The Hybridosome™ technology is a nanoparticle delivery modality combining natural and synthetic components for tissue-targeted, non-viral gene therapy delivery; the company states potential advantages in reduced immunogenicity, increased payload capacity and targeted delivery. Together with proprietary gene vectors and scalable manufacturing, these form an integrated gene therapy platform.
Constructs produced on the platform are intended for use across AAV, mRNA, lentiviral vector and other genetic medicine applications. The company is backed at Series A stage.
